Developer docs
API playgroundTry for free, no card

Search company profiles

FamiCordTx

Full company profile

uuid003gfsr

Namestring
FamiCordTx
Legal namestring
FamiCordTx S.A.
Websiteurl
famicordtx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

FamiCordTx S.A. is a Polish clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for the treatment of hematological malignancies, with a primary focus on B-cell cancers. The company was founded in 2019 as a subsidiary of the FamiCord capital group, which has over 20 years of operating history and is associated with umbilical cord blood banking infrastructure. Its core technology combines cell therapy and genetic engineering, using allogeneic effector lymphocytes sourced from cord blood and engineered to express CAR receptors (including CD19-targeting constructs) to create what the company describes as the world's first off-the-shelf allogeneic populational bank CAR-T therapy designed for immediate administration.

The technical platform addresses known limitations of autologous CAR-T approaches — namely individualized manufacturing delays, high cost, and exclusion of patients too severely ill to wait for personalized production. The portfolio includes an allogeneic CAR-T cancer therapy product, a targeted ex-vivo gene therapy program, and the allogeneic effector lymphocyte platform itself. Manufacturing is intended to comply with GMP standards, and the scientific team is described as internationally sourced (US, Poland, Australia) with embedded PhD programs, though no named principal investigators or management roster is disclosed.

The business model is currently grant-funded rather than revenue-generating. The company does not publicly disclose pricing, and its only disclosed monetary inflow is a PLN 20,802,247.86 (~USD 5M) grant from Poland's Medical Research Agency (Agencja Badań Medycznych) awarded in 2022 under the ABM/2022/6 program for targeted/personalized medicine based on nucleic acid therapies, against a total project value of PLN 44,541,120.72. Distribution upon commercialization is expected to flow through hospitals, cancer treatment centers, and hematology departments, but no commercial customers, headcount figures, or product launch dates are disclosed.

Short descriptiontext

FamiCordTx is a Polish biotech subsidiary of the FamiCord Group developing allogeneic CAR-T cell therapies from cord blood for blood cancer patients. The pre-clinical company is grant-funded by Poland's Medical Research Agency and targets B-cell malignancies with off-the-shelf administration.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWarszawa, Poland
HQ citystring
Warszawa
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Allogeneic CAR-T therapy, Cell and gene therapy, Cord blood biotech, Cancer immunotherapy, Bioprocess development
Industry3 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell and Gene Therapy
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

FamiCordTx develops allogeneic (off-the-shelf) CAR-T cell therapies and ex-vivo gene therapies built on cord blood–derived effector lymphocytes to treat hematological malignancies. Its pipeline targets relapsed/refractory B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma using standardized cellular drug products manufactured from umbilical cord blood rather than patient-autologous cells. The company operates as a clinical-stage biopharmaceutical developer leveraging its FamiCord Group parent's cord blood supply for scalable raw material access.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

FamiCordTx is a biotech company developing a portfolio of allogeneic cell and gene therapies focused on CAR-T cancer treatment. The company's core product is an allogeneic CAR-T therapy based on a populational bank of cord blood-derived effector lymphocytes, designed to provide immediate off-the-shelf administration to patients with B-cell malignancies. The product portfolio includes CAR-T cancer therapy and ex-vivo gene therapy platforms, with the goal of making advanced gene and cell therapies accessible for everyone.

Product and service3 records
1CAR-T Cancer Therapy (allogeneic)
CategoryCell therapy — CAR-T immunotherapy
Description

Allogeneic (off-the-shelf) CAR-T cell therapy targeting hematological malignancies including relapsed/refractory B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma; intended for licensing or clinical development partners and, post-approval, hospital-based oncology centers.

2Ex-Vivo Gene Therapy
CategoryGene therapy
Description

Ex-vivo gene therapy platform utilizing cord blood–derived effector lymphocytes as the cellular substrate for genetic modification, intended to extend the company's cellular immunotherapy capabilities beyond CAR-T into broader engineered cell therapies.

3Allogeneic Effector Lymphocytes (cellular drug product)
CategoryCellular drug product / cell therapy platform input
Description

Off-the-shelf allogeneic effector lymphocytes isolated and expanded from umbilical cord blood, serving as the standardized cellular starting material for both the allogeneic CAR-T and ex-vivo gene therapy programs.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers4 records
TypeDirect peer
Description

Clinical-stage leader in allogeneic CAR-T cell therapy targeting CD19 and BCMA for hematological malignancies. Most directly comparable peer — both companies pursue off-the-shelf allogeneic CAR-T architectures, though Allogene uses peripheral blood-derived T-cells rather than cord blood.

TypeDirect peer
Description

Pioneer in gene-edited allogeneic CAR-T using TALEN-based cell engineering, with clinical programs in B-cell malignancies and partnerships with Allogene and Servier. Direct competitor building off-the-shelf CAR-T banks with gene-editing platforms similar in spirit to FamiCordTx's populational bank approach.

TypeDirect peer
Description

Develops allogeneic CAR-T therapies (CTX110 for CD19) using CRISPR/Cas9 gene editing to create off-the-shelf products. Direct competitor in the allogeneic CAR-T space with significant capital and a Vertex partnership; competes for the same off-the-shelf value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FamiCordTx

Cell and Gene Therapyfamicordtx.com

FamiCordTx is a Polish biotech subsidiary of the FamiCord Group developing allogeneic CAR-T cell therapies from cord blood for blood cancer patients. The pre-clinical company is grant-funded by Poland's Medical Research Agency and targets B-cell malignancies with off-the-shelf administration.

What FamiCordTx does

FamiCordTx S.A. is a Polish clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for the treatment of hematological malignancies, with a primary focus on B-cell cancers. The company was founded in 2019 as a subsidiary of the FamiCord capital group, which has over 20 years of operating history and is associated with umbilical cord blood banking infrastructure. Its core technology combines cell therapy and genetic engineering, using allogeneic effector lymphocytes sourced from cord blood and engineered to express CAR receptors (including CD19-targeting constructs) to create what the company describes as the world's first off-the-shelf allogeneic populational bank CAR-T therapy designed for immediate administration.

The technical platform addresses known limitations of autologous CAR-T approaches — namely individualized manufacturing delays, high cost, and exclusion of patients too severely ill to wait for personalized production. The portfolio includes an allogeneic CAR-T cancer therapy product, a targeted ex-vivo gene therapy program, and the allogeneic effector lymphocyte platform itself. Manufacturing is intended to comply with GMP standards, and the scientific team is described as internationally sourced (US, Poland, Australia) with embedded PhD programs, though no named principal investigators or management roster is disclosed.

The business model is currently grant-funded rather than revenue-generating. The company does not publicly disclose pricing, and its only disclosed monetary inflow is a PLN 20,802,247.86 (~USD 5M) grant from Poland's Medical Research Agency (Agencja Badań Medycznych) awarded in 2022 under the ABM/2022/6 program for targeted/personalized medicine based on nucleic acid therapies, against a total project value of PLN 44,541,120.72. Distribution upon commercialization is expected to flow through hospitals, cancer treatment centers, and hematology departments, but no commercial customers, headcount figures, or product launch dates are disclosed.

FamiCordTx firmographics

Firmographics
Name
FamiCordTx
Legal name
FamiCordTx S.A.
Website
https://famicordtx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
FamiCordTx is a Polish biotech subsidiary of the FamiCord Group developing allogeneic CAR-T cell therapies from cord blood for blood cancer patients. The pre-clinical company is grant-funded by Poland's Medical Research Agency and targets B-cell malignancies with off-the-shelf administration.
Ownership category
akta.pro rank

FamiCordTx industry classification

Industry
Product category
Cell and Gene Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Allogeneic CAR-T therapy
  • Cell and gene therapy
  • Cord blood biotech
  • Cancer immunotherapy
  • Bioprocess development

Where FamiCordTx is headquartered

Location

Headquarters

HQ city
Warszawa
HQ country
Poland
HQ region
Europe

Offices1 record

Markets served

FamiCordTx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain

Distribution channels1 record

Marketing channels1 record

FamiCordTx product offering

Product offering

Core offering

FamiCordTx develops allogeneic (off-the-shelf) CAR-T cell therapies and ex-vivo gene therapies built on cord blood–derived effector lymphocytes to treat hematological malignancies. Its pipeline targets relapsed/refractory B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma using standardized cellular drug products manufactured from umbilical cord blood rather than patient-autologous cells. The company operates as a clinical-stage biopharmaceutical developer leveraging its FamiCord Group parent's cord blood supply for scalable raw material access.

Product overview

FamiCordTx is a biotech company developing a portfolio of allogeneic cell and gene therapies focused on CAR-T cancer treatment. The company's core product is an allogeneic CAR-T therapy based on a populational bank of cord blood-derived effector lymphocytes, designed to provide immediate off-the-shelf administration to patients with B-cell malignancies. The product portfolio includes CAR-T cancer therapy and ex-vivo gene therapy platforms, with the goal of making advanced gene and cell therapies accessible for everyone.

Differentiator

Problem solved

Functional benefit

Products and services

  • CAR-T Cancer Therapy (allogeneic) Allogeneic (off-the-shelf) CAR-T cell therapy targeting hematological malignancies including relapsed/refractory B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma; intended for licensing or clinical development partners and, post-approval, hospital-based oncology centers.
  • Ex-Vivo Gene Therapy Ex-vivo gene therapy platform utilizing cord blood–derived effector lymphocytes as the cellular substrate for genetic modification, intended to extend the company's cellular immunotherapy capabilities beyond CAR-T into broader engineered cell therapies.
  • Allogeneic Effector Lymphocytes (cellular drug product) Off-the-shelf allogeneic effector lymphocytes isolated and expanded from umbilical cord blood, serving as the standardized cellular starting material for both the allogeneic CAR-T and ex-vivo gene therapy programs.

Companies that use FamiCordTx

Customer profile

Segments1 record

Ideal customer profiles1 record

FamiCordTx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

FamiCordTx partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

FamiCordTx competitors and assessment

Company assessment

Direct peers

  • Allogene Therapeutics: Clinical-stage leader in allogeneic CAR-T cell therapy targeting CD19 and BCMA for hematological malignancies. Most directly comparable peer — both companies pursue off-the-shelf allogeneic CAR-T architectures, though Allogene uses peripheral blood-derived T-cells rather than cord blood.
  • Cellectis: Pioneer in gene-edited allogeneic CAR-T using TALEN-based cell engineering, with clinical programs in B-cell malignancies and partnerships with Allogene and Servier. Direct competitor building off-the-shelf CAR-T banks with gene-editing platforms similar in spirit to FamiCordTx's populational bank approach.
  • CRISPR Therapeutics: Develops allogeneic CAR-T therapies (CTX110 for CD19) using CRISPR/Cas9 gene editing to create off-the-shelf products. Direct competitor in the allogeneic CAR-T space with significant capital and a Vertex partnership; competes for the same off-the-shelf value proposition.

Peers

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights3 records

Customer concentration

FamiCordTx social profiles

Digital presence

FamiCordTx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FamiCordTx leadership team

Management profile

Number of profiles

Profiles1 record

FamiCordTx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FamiCordTx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FamiCordTx

What does FamiCordTx do?

FamiCordTx develops allogeneic (off-the-shelf) CAR-T cell therapies and ex-vivo gene therapies built on cord blood–derived effector lymphocytes to treat hematological malignancies. Its pipeline targets relapsed/refractory B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma using standardized cellular drug products manufactured from umbilical cord blood rather than patient-autologous cells. The company operates as a clinical-stage biopharmaceutical developer leveraging its FamiCord Group parent's cord blood supply for scalable raw material access.

Is FamiCordTx a public or private company?

FamiCordTx is a private company. It is classified as corporate owned and is currently operating.

When was FamiCordTx founded?

FamiCordTx was founded in 2019. It employs 11 to 50 people.

Where is FamiCordTx based?

FamiCordTx is headquartered in Warszawa, Poland, in the Europe region.

Who are FamiCordTx's main competitors?

Direct peers on record are Allogene Therapeutics, Cellectis and CRISPR Therapeutics. Precision BioSciences is listed as a peer.

Does FamiCordTx have an API?

No public API is recorded for FamiCordTx.

What industry is FamiCordTx in?

FamiCordTx's product category is Cell and Gene Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales